(3r)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone has been researched along with Neuralgia in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hayashi, S; Kato, A; Mizuno, K; Morita, A; Nakata, E; Ohashi, K; Yamamura, K | 1 |
| Adam, JM; Baker, J; Boyce, S; Campbell, R; Clark, JK; Cottney, JE; Davies, K; Deehan, M; Everett, K; Fields, R; Francis, S; Jeremiah, F; Kiyoi, T; Maidment, M; Martin, I; Morrison, A; Prosser, A; Ratcliffe, P; Schulz, J; Wishart, G | 1 |
| Barth, F; Cavasotto, CN; Chen, SR; Diaz, F; Diaz, P; Knight, L; Mackie, K; McDaniel, SW; Pan, HL; Petrov, RR; Wager-Miller, J | 1 |
3 other study(ies) available for (3r)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone and Neuralgia
| Article | Year |
|---|---|
Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: de
Topics: Analgesics; Animals; Benzimidazoles; Drug Design; Drug Evaluation, Preclinical; Humans; Microsomes, Liver; Neuralgia; Nociceptin Receptor; Pyrroles; Rats; Receptors, Opioid; Structure-Activity Relationship | 2010 |
Low brain penetrant CB1 receptor agonists for the treatment of neuropathic pain.
Topics: Animals; Brain; Caco-2 Cells; Drug Design; Humans; Indoles; Mice; Neuralgia; Oxadiazoles; Rats; Receptor, Cannabinoid, CB1 | 2012 |
Mastering tricyclic ring systems for desirable functional cannabinoid activity.
Topics: Animals; Carbazoles; Dose-Response Relationship, Drug; Humans; Models, Molecular; Molecular Structure; Neuralgia; Rats; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Structure-Activity Relationship | 2013 |